Roche Holding (RHHBY)
(Delayed Data from OTC)
$39.61 USD
+0.28 (0.71%)
Updated Sep 18, 2024 03:59 PM ET
3-Hold of 5 3
B Value C Growth A Momentum B VGM
Price, Consensus and EPS Surprise
RHHBY 39.61 +0.28(0.71%)
Will RHHBY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RHHBY
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Tap the Weight-Loss Drug Market With These ETFs
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
Regeneron, SNY Win FDA Approval for a Broader Dupixent Label
Roche Gets FDA Approval for Subcutaneous Formulation of Tecentriq
Other News for RHHBY
Roche says Xofluza reduces transmission of influenza viruses
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
Barclays Keeps Their Hold Rating on Roche Holding AG (RHHVF)
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections